Compass Therapeutics Investor Presentation Deck
CTX-471: Potential Best-in-Class CD137 Agonist
CTX-471: next generation CD137 agonist
Fully human, IgG4, optimized affinity for agonistic antibody
Unique epitope: non-ligand blocking
Phase 1 Study Update
Monotherapy in post checkpoint inhibitor patients
Monotherapy Phase 1a multiple ascending dose study completed
Near PR in a patient with mucosal melanoma
Prolonged stable disease in two patients with NSCLC
MTD defined by immune thrombocytopenia
Monotherapy Phase 1b dose expansion study nearing completion
4 PRs observed so far: small cell lung cancer, mucosal melanoma, metastatic
melanoma, and mesothelioma
●
●
●
COMPASS NOVEL EPITOPE WITH DIFFERENTIATED ACTIVITY OBSERVED IN EXTENSIVE PRECLINICAL DATA*
THERAPEUTICS
Urelumab, 3H3
CD137
CTX-471
CD137L
Utomilumab
*Eskiocak, et al. JCI Insight. 2020;5(5):e133647
30View entire presentation